The Therapeutic Goods Administration is experiencing system issues linked to global Microsoft outages. Some services may be disrupted and we may take longer to respond to email and phone contact during this time.
IVABRADINE GPPL, IVABRADINE GXP, COBADINE, APO-IVABRADINE, CORALIVAN, CIVABRADINE, IVABRADINE NHPL (Generic Partners Pty Ltd)
Product name
IVABRADINE GPPL, IVABRADINE GXP, COBADINE, APO-IVABRADINE, CORALIVAN, CIVABRADINE, IVABRADINE NHPL
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
166 working days (255)
Active ingredients
ivabradine (as hydrochloride)
Registration type
New generic medicine
Indication
IVABRADINE GPPL, IVABRADINE GXP, COBADINE, APO-IVABRADINE, CORALIVAN, CIVABRADINE, IVABRADINE NHPL (tablets) is indicated for the treatment of chronic stable angina and chronic heart failure.